# Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

> **NCT02474706** · PHASE4 · TERMINATED · sponsor: **Central Hospital, Nancy, France** · enrollment: 6 (actual)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** Cefoxitin
- **DRUG:** imipenem

## Key facts

- **NCT ID:** NCT02474706
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Lack of recruitment
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474706, "Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02474706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*